Additional insight into the biology of ER - positive breast cancers, particularly the higher
risk luminal B cancers, could aid in identifying potential targets and new, effective therapies.
The team therefore analyzed the case history of 890 breast cancer patients and found that low Numb - 1 and -2 levels correlated with an increased
risk of aggressive, metastatic disease, particularly for the
luminal subtype of breast cancers, which tend to retain a normal, functional copy of the p53 gene.